Skip to main content

Coya Therapeutics, Inc.

COYA
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001835022

No open-market purchases or sales by Coya Therapeutics, Inc. insiders were filed in the last 90 days; 51 institutions reported holding it in 13F filings for Q3 2026, worth $36.6M in total; Greenlight Capital is the only superinvestor holding it.

Key figures

Market capClose on Nov 19, 2026
$69.9M
Insider buysOpen market, last 90 days
0
Insider sellsOpen market, last 90 days
0
13F holdersQ3 2026, −2 vs. previous quarter
51
13F valueReported value at the end of Q3 2026
$36.6M
Superinvestors holdingAt the end of Q3 2026
1

Price chart

From SEC filings, in USD.

Revenue, FY2025
$7.95M
+123.6% year over year
Net income, FY2025
-$21.2M
No comparable prior period
Free cash flow, FY2025
–
No comparable prior period
Revenue, Q3 FY2026
$234.1K
−93.4% year over year

Revenue flow, FY2025

Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.

Net loss for FY2025: $21.2M (267.1% of revenue).

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest
1.41M
Shares sold short
Change
+156.1K
+12.4% vs. previous
Days to cover
11.89
At average daily volume

Superinvestors holding COYA, Q3 2026

Go to the superinvestors tab

1 superinvestor reports holding Coya Therapeutics, Inc. on Form 13F. Percentages are the stock's share of each portfolio.

Greenlight Capital

David Einhorn

0.3%

Coya Therapeutics, Inc.'s share of the portfolio

Shares
2,335,540
Value
$11.7M

Latest insider trades

See all insider trades

Open-market purchases and sales by Coya Therapeutics, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Nov 14, 2024 (view filing)Nov 14Same daySnyder David SChief Financial OfficerPPurchaseCommon Stock, par value $0.0001 per share+1.80K$7.19+$12.9K+25.7%8.80K after
Nov 13, 2024 (view filing)Nov 13Same daySwaminathan ArunChief Executive OfficerPPurchaseCommon Stock, par value $0.0001 per share+5.00K$7.36+$36.8K+100.0%10.0K after
Nov 12, 2024 (view filing)Nov 111 dayGrossman FredChief Medical OfficerPPurchaseCommon Stock, par value $0.0001 per share+2.71K$7.37+$20.0KNew position2.71K after
Nov 12, 2024 (view filing)Nov 111 daySwaminathan ArunChief Executive OfficerPPurchaseCommon Stock, par value $0.0001 per share+5.00K$7.34+$36.7KNew position5.00K after
Mar 5, 2024 (view filing)Aug 22, 2023196 daysLateLee AnnDirectorPPurchaseCommon Stock, par value $0.0001 per share+1.00K$3.62+$3.62K+6.1%17.5K after
Jan 4, 2023 (view filing)8:30 AM ETJan 31 dayLee AnnDirectorPPurchaseCommon Stock, par value $0.0001 per share+10.0K––New position10.0K after
Jan 4, 2023 (view filing)8:30 AM ETJan 31 dayLee AnnDirectorPPurchaseCommon Stock, par value $0.0001 per share+5.00K–––9.48K afterDerivative
Jan 4, 2023 (view filing)Jan 31 dayBerman HowardChief Executive OfficerPPurchaseCommon Stock, par value $0.0001 per share+10.0K––New position10.0K afterFrom original
Jan 4, 2023 (view filing)Jan 31 dayBerman HowardChief Executive OfficerPPurchaseCommon Stock, par value $0.0001 per share+5.00K–––5.00K afterFrom originalDerivative
Jan 4, 2023 (view filing)Jan 31 dayHepner AdrianChief Medical OfficerPPurchaseCommon Stock, par value $0.0001 per share+10.0K––New position10.0K after

Top 10 13F holders, Q3 2026

See all 51 holders

The largest institutional positions in Coya Therapeutics, Inc. at the end of Q3 2026; share changes are against Q2 2026.

Institutions holding COYA in Q3 2026
InstitutionSharesValue% of portfolioChange in sharesAction
DME Capital Management, LPSuperinvestorGreenlight Capital2,335,540$11.7M0.33%00.0%Unchanged
Vanguard Capital Management LLC852,751$4.27M0.00%+10,531+1.3%Added
AIGH Capital Management LLC631,912$3.17M0.36%00.0%Unchanged
Alyeska Investment Group, L.P.400,000$2.00M0.01%−400,000−50.0%Reduced
CM Management, LLC400,000$2.00M1.34%00.0%Unchanged
Private Management Group Inc380,876$1.91M0.05%−3,341−0.9%Reduced
Marshall Wace, LLP323,849$1.62M0.00%+74,056+29.6%Added
Prosight Management, LP229,600$1.15M0.22%+59,600+35.1%Added
Geode Capital Management, LLC211,036$1.06M0.00%−17,207−7.5%Reduced
Dimensional Fund Advisors LP169,458$849.1K0.00%+13,541+8.7%Added

Holders of 5% or more of COYA

See all 2 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Coya Therapeutics, Inc..

Largest holders of COYA from 13D and 13G filings
HolderLatest formStakeChangeFirst filedLatest filingFiling
DME Capital Management, LPSuperinvestorGreenlight Capital13G/A9.90%1.65M shares–Feb 14, 20251 filingFeb 14, 2025SEC
Dr. Reddy's Laboratories, Inc.13G9.70%2.27M sharesNewMar 12, 20261 filingMar 12, 2026SEC